Projections and Predictions
J&J brushes off tariff headwinds with raised forecast, oncology surge
J&J, United States, Sales – occupational activity, Neoplasms, Johnson and Johnson, Caplyta, Intra-Cellular Therapies, Raised, Increased, Growth, Projections and Predictions
Eisai Revises Leqembi Sales Forecast for 2027, Remains Optimistic About Growth
Leqembi, Alzheimer’s disease, sales forecast, Eisai, Biogen, revenue projection
Eisai Slashes Leqembi Sales Forecast Amid Continued Launch Challenges
Eisai, Leqembi, Alzheimer’s disease, sales forecast, revenue expectations, Biogen, pharmaceutical industry
Amgen Boosts Full-Year Sales Forecast Following Horizon-Driven Revenue Surge
Amgen, full-year sales forecast, Horizon acquisition, revenue growth, pharmaceutical industry
Sanofi’s Dupixent Sales Surpass €3 Billion for the First Time
Sanofi, Dupixent, quarterly sales, record high, asthma medicine, earnings forecast
GSK’s Vaccine Sales Surge Continues, Boosting 2024 Outlook
GSK, GlaxoSmithKline, vaccine sales, 2024 forecasts, pharmaceutical industry, revenue growth, COVID-19 vaccines, Shingrix, healthcare sector
Merck & Co.’s Q1 Success Driven by Keytruda, Ups 2024 Outlook
Merck & Co., Q1 earnings, Keytruda, pharmaceuticals, cancer treatment, 2024 forecast
Arrowhead’s Plozasiran Projected to Surpass $700M in Sales by 2032, Addressing Major Unmet Needs in Dyslipidemia Treatment
Arrowhead Pharmaceuticals, Plozasiran, Dyslipidemia, GlobalData, Sales Forecast, $700M, 2032, Unmet Needs, Triglyceride Reduction, APOC3 Targeting, SHTG (Severe Hypertriglyceridemia), FCS (Familial Chylomicronemia Syndrome), Mixed Dyslipidemia